$Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic$
Código QR

Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic

Colorectal cancer (CRC) is one of the leading cancers in terms of prevalence and mortality. Almost 1/4 of patients with CRC have metastases at the initial presentation. The survival rate of this group of patients remains low. With the onset of the COVID-19 pandemic, cancer patients have faced diffic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marina I. Sekacheva, Anastasia S. Fatyanova, Daur A. Meretukov, Angelina V Zhilenkova, Aleksandr S. Rusanov, Aleksandr A. Rozhkov, Anastasiia A. Guryanova, Nikolay N. Bagmet
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	colorectal cancer covid-19 chemotherapy targeted therapy regorafenib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/74b49f25f4074c698a61ce570af6f103
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:74b49f25f4074c698a61ce570af6f103
record_format	dspace
spelling	oai:doaj.org-article:74b49f25f4074c698a61ce570af6f1032021-11-30T16:55:01ZRefractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic1815-14341815-144210.26442/18151434.2021.2.200904https://doaj.org/article/74b49f25f4074c698a61ce570af6f1032021-08-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/71019/pdfhttps://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Colorectal cancer (CRC) is one of the leading cancers in terms of prevalence and mortality. Almost 1/4 of patients with CRC have metastases at the initial presentation. The survival rate of this group of patients remains low. With the onset of the COVID-19 pandemic, cancer patients have faced difficulties in getting diagnosis or treatment, which could potentially lead to an increase in late-stage tumors and mortality. This situation required changes in approaches to the treatment of cancer patients, such as replacing drugs with tablet forms, schemes with long intervals, and much more. It is known that about 50% of patients with metastatic colorectal cancer survive in satisfactory condition until the 3rd line drug therapy or longer. One of the main drugs for this category of patients is regorafenib, which, thanks to the tablet formulation, has become especially important in the COVID-19 pandemic. In numerous clinical studies, the drug showed an increase in patient overall survival and good safety profile. In addition, there is growing evidence of the effect of regorafenib on tumor sensitivity to treatment with platinum drugs, irinotecan, and EGFR inhibitors.Marina I. SekachevaAnastasia S. FatyanovaDaur A. MeretukovAngelina V ZhilenkovaAleksandr S. RusanovAleksandr A. RozhkovAnastasiia A. GuryanovaNikolay N. BagmetIP Habib O.N.articlecolorectal cancercovid-19chemotherapytargeted therapyregorafenibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 2, Pp 256-259 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	colorectal cancer covid-19 chemotherapy targeted therapy regorafenib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	colorectal cancer covid-19 chemotherapy targeted therapy regorafenib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Marina I. Sekacheva Anastasia S. Fatyanova Daur A. Meretukov Angelina V Zhilenkova Aleksandr S. Rusanov Aleksandr A. Rozhkov Anastasiia A. Guryanova Nikolay N. Bagmet Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic
description	Colorectal cancer (CRC) is one of the leading cancers in terms of prevalence and mortality. Almost 1/4 of patients with CRC have metastases at the initial presentation. The survival rate of this group of patients remains low. With the onset of the COVID-19 pandemic, cancer patients have faced difficulties in getting diagnosis or treatment, which could potentially lead to an increase in late-stage tumors and mortality. This situation required changes in approaches to the treatment of cancer patients, such as replacing drugs with tablet forms, schemes with long intervals, and much more. It is known that about 50% of patients with metastatic colorectal cancer survive in satisfactory condition until the 3rd line drug therapy or longer. One of the main drugs for this category of patients is regorafenib, which, thanks to the tablet formulation, has become especially important in the COVID-19 pandemic. In numerous clinical studies, the drug showed an increase in patient overall survival and good safety profile. In addition, there is growing evidence of the effect of regorafenib on tumor sensitivity to treatment with platinum drugs, irinotecan, and EGFR inhibitors.
format	article
author	Marina I. Sekacheva Anastasia S. Fatyanova Daur A. Meretukov Angelina V Zhilenkova Aleksandr S. Rusanov Aleksandr A. Rozhkov Anastasiia A. Guryanova Nikolay N. Bagmet
author_facet	Marina I. Sekacheva Anastasia S. Fatyanova Daur A. Meretukov Angelina V Zhilenkova Aleksandr S. Rusanov Aleksandr A. Rozhkov Anastasiia A. Guryanova Nikolay N. Bagmet
author_sort	Marina I. Sekacheva
title	Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic
title_short	Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic
title_full	Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic
title_fullStr	Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic
title_full_unstemmed	Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic
title_sort	refractory metastatic colorectal cancer: challenges and solutions during the covid-19 pandemic
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/74b49f25f4074c698a61ce570af6f103
work_keys_str_mv	AT marinaisekacheva refractorymetastaticcolorectalcancerchallengesandsolutionsduringthecovid19pandemic AT anastasiasfatyanova refractorymetastaticcolorectalcancerchallengesandsolutionsduringthecovid19pandemic AT daurameretukov refractorymetastaticcolorectalcancerchallengesandsolutionsduringthecovid19pandemic AT angelinavzhilenkova refractorymetastaticcolorectalcancerchallengesandsolutionsduringthecovid19pandemic AT aleksandrsrusanov refractorymetastaticcolorectalcancerchallengesandsolutionsduringthecovid19pandemic AT aleksandrarozhkov refractorymetastaticcolorectalcancerchallengesandsolutionsduringthecovid19pandemic AT anastasiiaaguryanova refractorymetastaticcolorectalcancerchallengesandsolutionsduringthecovid19pandemic AT nikolaynbagmet refractorymetastaticcolorectalcancerchallengesandsolutionsduringthecovid19pandemic
_version_	1718406451005751296

Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic

Ejemplares similares